Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01368796
Other study ID # H11-01457
Secondary ID
Status Completed
Phase Phase 4
First received June 6, 2011
Last updated April 14, 2015
Start date July 2011
Est. completion date May 2012

Study information

Verified date April 2015
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Based on information from several years of looking at Influenza vaccination doctors know that:

- Older adults suffer the worst illness and most deaths caused by Influenza illness of all age groups.

- Older adults do not seem to get as good a level of protection as younger adults after getting the usual seasonal Influenza vaccine.

Because of this information doctors wonder if one of the new seasonal Influenza vaccines is more effective or more acceptable.

This study has been designed to answer some of these questions. On this study doctors will compare 2 new vaccines against the usual seasonal influenza vaccine for protectiveness using several different testing methods (including the usual tests) and for acceptability.


Description:

This study is prospective, multicenter, randomized, evaluator-blinded, controlled, parallel group study of 3 licensed seasonal influenza vaccine products conducted in seniors, with a 4th vaccine included in a substudy of cellular immune responses.

Ambulatory adults 65+ years of age, in good health or with stable health conditions, given TIV within the past 2 years, will be recruited in multiple Canadian centres. Subjects can be dwelling in the community or in centers providing minimal assisted living support. A total of 930 subjects will be enrolled.

Subjects will be centrally (electronically) randomized to receive either TIV, IDV or AIV on Day 0. Three blood samples will be collected (1 pre and 2 post vaccination) to measure HAI antibody responses to each virus strain (H1N1, H3N2 and B) in each vaccine, using standardized assays. Randomly selected subsets of sera from each study group will also be tested for neutralizing antibody and for cross-protection against drift variants of H3N2, H1N1 and B viruses. In a subset of subjects in Vancouver, randomization assignments will include TIV2 and extra blood samples will be obtained 0, 21 and 72 days post vaccination for CMI testing. Safety assessments will be conducted on Day 7, Day 21 and Day 180 following vaccination. Acceptability of each product, reflecting the frequency, severity and tolerability of adverse effects, will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 953
Est. completion date May 2012
Est. primary completion date December 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Written informed consent provided by the subject, who can be male or female

- Subjects who the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, record safety observations and able to converse with study personnel including by personal telephone)

- Age 65 years or older at Visit 1

- Generally good health (stable chronic conditions acceptable), living independently or with minimal assistance (Clinical Frailty score 1-5) (33) and able to attend clinic appointments

- Receipt of at least one dose of TIV within the previous 2 influenza seasons, documented by written record or attested by a confident personal recollection. This refers to the trivalent seasonal vaccine, not the H1N12009 pandemic vaccine.

Exclusion Criteria:

- receipt of non-study influenza vaccine for 2011-12

- receipt of any live vaccine within 4 weeks or inactivated vaccine within one week of Visit 1 or planned administration of any non-study vaccines between Visits 1 and 2

- systemic hypersensitivity to influenza vaccine, hen's eggs or other vaccine constituent (eg neomycin sulphate, kanamycin, formalin)

- severe reaction to any previous influenza vaccine or vaccine component

- bleeding disorder, including anticoagulant therapy or thrombocytopenia, that contraindicates IM injection or blood collection (does not include daily low-dose ASA).

- incapacity to provide fully informed consent or be attentive to follow-up observations, resulting from cognitive impairment, abuse of alcohol, drug addiction

- lack of telephone access, inadequate fluency in English (or French in applicable jurisdictions), uncertain availability during the 3 week study participation period or for the 6 month follow-up visit

- immune compromise resulting from disease or immunosuppressive systemic medication use within 3 months of V1

- receipt of blood or blood product within 3 months of V1

- unstable medical condition, as indicated by a requirement for hospitalization or a substantial medication change to stabilize said condition within previous 3 months

- Clinical Frailty score of 6-7 (moderately frail or severely frail)

- history of Guillain-Barré syndrome

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Agriflu
0.5mL dose IM vaccination
Fluad
0.5mL dose of vaccine given IM
Intanza
0.5mL dose vaccine given IM
Vaxigrip
0.5mL dose vaccine given IM

Locations

Country Name City State
Canada Canadian Centre for Vaccinology Dalhousie University Halifax Nova Scotia
Canada McMaster University Hamilton Ontario
Canada McGill University Health Center - Vaccine Study Center Montreal Quebec
Canada The Ottawa Hospital Research Institute, University of Ottawa Ottawa Ontario
Canada Unité de Recherche en Santé Publique (CHUQ), Quebec City Quebec
Canada University of Toronto, Mt Sinai Hospital Toronto Ontario
Canada University of British Columbia, VITALiTY Research Center Vancouver British Columbia
Canada University of Manitoba, Department of Medicine Winnipeg Manitoba

Sponsors (2)

Lead Sponsor Collaborator
University of British Columbia PHAC/CIHR Influenza Research Network

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary HAI response The primary outcome measures will be the 3-week post-vaccination immune (HAI) responses to the 3 vaccine strains present in each product, assessed by the EMEA/CHMP criteria for evaluation of immune responses to influenza vaccines in persons >60 years of age. Day 0; Day 21; Day 180 No
Secondary Seroprotection rates using microneutralization titres and cytokine testing As secondary immunologic outcomes seroprotection rates will be compared between the products using a higher titer (=160) as threshold. Microneutralization titers will be compared among products at the 3 sampling points, using sera from 100 subjects per group. Cross-protection afforded by each vaccine against drift variants of H3N2, H1N1 and B viruses will be assessed using serum panels selected from 50 subjects in each group. Cellular immune responses elicited will be compared in subgroups of 30 subjects per vaccine in the CMI subjset. Day 0; Day 21; and Day 70 No
Secondary Safety and Acceptability Safety and acceptability of the vaccines will also be examined and compared as the safety outcomes. The primary outcome measurements will be the rates of local adverse events (pain, redness, swelling, itchiness) as rates of general adverse events are not expected to differ substantially among the products. Days 0-6; Day 21; Day 70; and Day 180 Yes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03285997 - A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age Phase 3
Recruiting NCT05996549 - Cost-effectiveness of the Influenza Vaccination Phase 4
Completed NCT04546854 - Influenza 2020/2021 N/A
Completed NCT05157425 - Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination N/A
Completed NCT01687517 - Efficacy and Safety of Influenza Vaccine During Sarcoidosis Phase 3
Completed NCT01180699 - Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients N/A
Completed NCT00760175 - Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients N/A
Completed NCT00542776 - Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine N/A
Completed NCT06304038 - Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
Recruiting NCT04086628 - Influenza Vaccine in Children With Asthma
Completed NCT02960815 - Imiquimod and Influenza Vaccine for Immunocompromised Patients Phase 2
Completed NCT00828555 - Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting N/A
Completed NCT04230343 - Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour N/A
Recruiting NCT03399357 - Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial N/A
Completed NCT02153671 - Immunogenicity of H5N1 Vaccine Following H5N2 Phase 2
Completed NCT00461981 - A Phase 2 Study to Evaluate Immune Responses of FluMist® Phase 2
Recruiting NCT05070494 - Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients Phase 4
Completed NCT04785794 - Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old Phase 1
Completed NCT05163847 - Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults Phase 1
Not yet recruiting NCT04355806 - Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors